# Sero-epidemiology to support decision-making for malaria elimination

## Isabel Byrne<sup>1</sup>, Elin Dumont<sup>1</sup>, Luca Nelli<sup>2</sup>, Gillian Stresman<sup>3, 1</sup>, Chris Drakeley<sup>1</sup> <sup>1</sup>Department of Infection Biology, London School of Hygiene and Tropical Medicine, <sup>2</sup>School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow, UK, <sup>3</sup> College of Public Health, University of South Florida, USA

Historic exposure

## Introduction

- Serology measures antibody responses which reflect previous exposure to pathogens
- Knowledge of malaria biomarker longevity allows **characterization of** recent (6-12 months) and past (within 20 years) exposure <sup>1, 2</sup>
- In comparison, **PCR/RDT diagnostics only detect concurrent infections** which are sparse at low-transmission
- In pre-elimination settings, surveys benefit from sensitive tools to detect residual transmission patterns<sup>3</sup>
- Population-level sero-epidemiology may provide added insight to support decision making in elimination

## **Aims & Objectives**

Aimed to assess added benefit of including serology in population-level surveys to support decision making in pre-elimination settings

- Include serology as diagnostic end-point in a multi-country survey
- Describe the sero-epidemiological patterns and prevalences
- Compare serological findings to PCR/RDT diagnostics
- Examine serology as tool to identify high risk populations

#### Methods



#### Surveys in 5 pre-elimination settings

Lao PDR, Vietnam, Philippines, Cape Verde, Peru 19,411 individuals RDT, PCR & dried blood spots



#### **Serology:** Luminex multiplex bead assays

Antigen	Exposure	Species
PfMSP119 PfAMA1	Historic	Plasmodium falciparum
Etramp5.Ag1	Recent	



#### **Classification of sero-positivity**

Unsupervised machine-learning approach **kmeans clustering** to define individuals as sero-positive Sero-prevalence and PCR prevalence calculated



#### Case study: Cape Verde risk groups

Sampled high and low risk groups based on recent travel Calculated relative risk for *P. falciparum* exposure between groups

Laos

Peru

Vietnam

Low risk

High risk Table 1 Number of individuals sampled per study site, PCR and sero-prevalence for recent and historic P. falciparum exposure



# Histo 2.2 (1 Low risk

Table 2: Results from Cape Verde case study: relative risk assessment comparing high risk traveller groups with "low risk" group

#### **Results Summary**

- At population-level, PCR diagnostics did not detect sufficient cases to inform knowledge of ongoing transmission
- Recent and historic exposure prevalences based on serology were higher than PCR prevalences
- Historic exposure was higher than recent in all settings
- Historic exposure increased with age in all settings
- Relative risk assessment found no difference in risk by PCR in travelling group compared to low-risk group

#### Conclusions

- years) than PCR do
- elimination settings



Elimination Settings', Frontiers in Public Health, 8, p. 480.





# BILL&MELINDA GATES foundation

Serology		PCR
oric	Recent	
I.1, 4.2)	0.4 (0.1, 1.2)	1 (1, 1)

- Relative risk assessment found significantly higher risk of historic
  - exposure by serology in high-risk group compared to low-risk group

• The results from the serological component of the surveys show that despite low levels of exposure, serology gives added levels of insight into ongoing and historic transmission in pre-elimination settings We have shown that serological results can be used to provide insight on transmission over a wider timeframe (6-12 months or up to 20

Historic exposure was higher than recent exposure, and increased with age, which are consistent with knowledge of transmission in pre-

Case study findings demonstrate use of serology to identify higher risk groups or settings. In comparison, this was not possible using PCR data. Potential for targeted interventions or surveillance

We highlight the **added information which can be extracted from** active surveillance samples with the operationally feasible addition of multiplex bead assay technology for serology.

1. Helb, D. A. et al. (2015) 'Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities', Proceedings of the National Academy of Sciences of the United States of America, 112(32) 2. van den Hoogen, L. L. et al. (2020) 'Comparison of Commercial ELISA Kits to Confirm the Absence of Transmission in Malaria

3. Surendra, H. et al. (2019) 'Analysis of serological data to investigate heterogeneity of malaria transmission: A community-based crosssectional study in an area conducting elimination in Indonesia', Malaria Journal, 18(1)